Fysiologie

Fysiologie is a Dutch biotechnology company focused on the development of novel therapeutic interventions for rare metabolic disorders, particularly lysosomal storage diseases. The company specializes in substrate reduction therapy (SRT) and is advancing a pipeline of small molecule inhibitors targeting glucosylceramide synthase. By modulating the metabolic pathways involved in glycosphingolipid synthesis, Fysiologie aims to provide more effective and accessible treatment options for patients with conditions such as Gaucher and Fabry disease. The company operates as a spin-off from academic research, leveraging deep expertise in physiology and biochemistry to address unmet medical needs in the orphan drug space.